9/26/2019 7:08:41 AM
Tetraphase Pharma Announces 1-for-20 Reverse Stock Split
6/24/2019 7:11:10 AM
Tetraphase Announces Presentation Of New Data On XERAVA And TP-6076
4/3/2019 8:05:43 AM
Tetraphase Pharma Presents Preclinical Data On TP-2846
10/23/2018 6:44:36 AM
Tetraphase Pharma Announces Positive Data From Post-Hoc Analysis Of Phase 3 Trials Demonstrating Efficacy Of XERAVA
10/11/2018 4:04:07 PM
Tetraphase Pharmaceuticals Announces Commercial Launch Of XERAVA In US
10/8/2018 6:31:43 AM
Tetraphase Pharma Announces Presentation Of Positive Data From Phase 3 Trials Of XERAVA
9/28/2018 4:09:14 PM
Tetraphase Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
9/19/2018 6:03:16 AM
Tetraphase Pharma To Present XERAVA And TP-6076 Data At IDWeek 2018
7/27/2018 8:37:31 AM
Tetraphase Receives Positive CHMP Opinion For Xerava As Treatment For Complicated Intra-Abdominal Infections
7/12/2018 4:02:47 PM
Tetraphase Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6/11/2018 6:34:45 AM
Tetraphase Pharma Announces Data From A Pooled Analysis Of IGNITE1 And IGNITE4 Phase 3 Trials Of Eravacycline
6/11/2018 6:34:31 AM
Tetraphase Announces Data From Pooled Analysis Of IGNITE1 And IGNITE4 Phase 3 Trials
4/12/2018 7:18:21 AM
Tetraphase To Present Data At 28th European Congress Of Clinical Microbiology And Infectious Diseases
2/27/2018 8:15:35 AM
Tetraphase Reports FDA Acceptance For Filing Of NDA Submission For Eravacycline